Flow References
Therapeutic/ | Title | Journal | Conference |
|---|---|---|---|
CAR T | Tracking Cellular Kinetics and Biodistribution of CAR T-Cells: Clinical Trial Considerations and Case Studies |
| WRIB |
CAR T | Why implementation of patient centric biomarker solutions for cell & gene therapies is vital? |
| TriCon |
ALL | Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy and Safety by Baseline CD22 | Clinical Cancer Research |
|
Heme | Development of DeepCytoFlow: A novel deep learning pipeline enabling automated gating of flow cytometry data |
| AACR |
Melanoma | Neoadjuvant Pembrolizumab and High Dose Interferon Alfa-2b in Resectable Regionally Advanced Melanoma | Clinical Cancer Research |
|
Heme | 2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedbacks | Bioanalysis |
|
Melanoma | Multimarker scores of Th1 and Th2 immune cellular profiles in baseline peripheral blood mononuclear cells predict response and immune related toxicity with CTLA4 blockade and IFNα in Melanoma | Translational Research |
|
Heme | Flow Cytometry in CAR-T Therapies: Challenges and Solutions |
| AAPS-OSD (Open Scientific Discussion) forum |
Heme | Best Practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell (CAR T) analyses | Clinical Cytometry |
|
AML (heme) | Best Practices for Validation of Measurable Residual Disease Assessments by Multiparameter Flow Cytometry in Emerging Clinical Trials of Acute Myeloid Leukemia |
| ASH |
Pan tumor | A multiparameter flow cytometry assay to monitor natural killer cell proliferation and activation in immuno-oncology clinical trials |
| SITC |
MF (heme) | A multiparameter flow cytometry assay to monitor megakaryocytes and leukemic cells in clinical trials of myelofibrosis patients |
| ICCS |
Heme | Monitoring CAR-T Cell Kinetics in Clinical Trials by Multiparameter Flow Cytometry: Benefits and Challenges | Clinical Cytometry |
|
Melanoma | Predictive value of circulating B cells and T cell subsets in melanoma patients treated with neoadjuvant ipilimumab and interferon α |
| ASCO |
Heme | High Dimensional Flow Cytometry in Immuno-Oncology |
| WRIB |
Heme | CAR-T monitoring by flow cytometry: Assuring Quality While Acknowledging Limitations |
| WRIB |
Pan Tumor | High Dimensional Flow Cytometery in IO |
| PMWC |
Heme | 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (SECTION 3 – Flow Cytometry Validation in Drug Discovery & Development & CLSI H62). | Bioanalysis |
|
Heme | 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (SECTION 5 – In vivo & Ex vivo Gene Therapy & Vaccine Bioanalytical Challenges). | Bioanalysis |
|
ALL | Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial | Leukemia Research |
|
ALL | Efficacy and Safety Outcomes in the Phase 3 INO-VATE Trial by Baseline CD22-Positivity Assessed by Local Laboratories |
| ASH |
Melanoma | Immunomodulatory effects of interleukin 2 in the circulation of melanoma patients and the added impact of VEGF inhibition with ziv-aflibercept |
| SITC |
Solid Tumor | Development of a slide-based multiplex immunofluorescent assay for detection of Helios degradation and DKY709 PD analysis |
| Novartis Onc Retreat |
Pan Tumor | Efficacy and Safety Biomarkers of Cancer lmmunotherapies Identified by Novel Digital Pathology and Flow Cytometry Approaches |
| Biomarkers and Precision Medicine Conference |
Melanoma | Application of High Complexity Flow Cytometry for Monitoring activated T-cells, T and B Regulatory Subsets in Combination Immunotherapy Trials, Melanoma Case Study |
| AACR |
Heme | On-going developments in CAR-T Bioanalytical Strategies & Challenges by Flow Cytometry |
| WRIB |
Heme | Molecular and flow cytometry analytical approaches and challenges for assessing cellular kinetics, efficacy and product characterization for gene therapy products |
| WRIB |
ALL | Comparison of CD22 Expression Levels Between Baseline and End of Treatment Among Patients treated with Inotuzumab Ozogamicin in Two Clinical Trials. |
| ASH |
Melanoma | Multimarker scores of Th1 and Th2 cellular profiles in baseline PBMCs predict response and toxicity with Ipilimumab and IFNα2b neoadjuvant therapy in Melanoma |
| SITC |
ALL | Genetic alterations in CD19 lead to CD19 negative relapse to CAR19 therapy in children and young adults with relapsed/refractory acute lymphoblastic leukemia. | Nature Medicine |
|
Melanoma | High Complexity All-in-One Flow Cytometry Assay for the Measurement of T-cell Activation, Checkpoint Inhibitor Expression and Proliferation of T-cells in Periphery as a Biomarker for Novel Immuno-oncology Clinical Trials |
| ICCS |
Melanoma | Assessment of Monocytes, MDSCs and Myeloid Cell Populations in Immuno-Oncology Clinical Trials by a Standardized High Complexity Flow Cytometry Approach |
| ICCS |
ALL | CAR-T Characterization by Flow Cytometry: Hurdles and Successes. Bioanalytical Conference; Madison, WI; July 2018 |
| Bioanalytical Conference |
ALL | Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INOVATE Trial: Efficacy and Safety by Baseline CD22 Expression Level |
| ASH |
ALL | Flow Cytometry Approaches for Characterizing Functional Persistence |
| AAPS |
Multiple | Biomarker Sample Stability: Why do we Care? |
| AAPS |
Multiple Myeloma | Analytical validation and clinical verification of phosphoprotein biomarker modulation using a novel preservation system-based flow cytometry assay in multiple myeloma clinical trials. |
| AACR |
Hematomalignancy | High complexity flow cytometry panels to monitor target expression, T-cell activation and suppression by novel immunotherapies in hematomalignancy clinical trials. |
| AACR |
| The Journey Towards Standardization for Validation of Fluorescent Cell-Based Assays. |
| ISCT |